Literature DB >> 28557587

The Prevalence of and Factors Associated With Receiving Concurrent Controlled Substance Prescriptions.

Erin A Ferries1, Aaron M Gilson2, Rajendar R Aparasu1, Hua Chen1, Michael L Johnson1, Marc L Fleming1.   

Abstract

BACKGROUND: Controlled substance prescription (CSP) use and abuse in the United States has become a public health epidemic. One common and dangerous indicator of abuse involves obtaining CSPs concurrently.
OBJECTIVE: The objective of this study was to identify the prevalence and factors associated with individuals receiving potentially inappropriate concurrent CSPs.
METHODS: This was a retrospective, cohort analysis using data from the 2013-2014 Texas prescription drug monitoring program (PDMP). Descriptive statistics and a multiple logistic regression analysis were conducted to examine the individual-level and prescription utilization factors associated with individuals obtaining concurrent CSPs.
RESULTS: Among Texas residents, 1,640,015 individuals (6.10% of all Texas residents and 15.99% of all CSP utilizers) were identified with at least one concurrent CSP combination. Concurrent opioid prescriptions were found to be the most prevalent concurrent use combination (n = 1,574,572). Having prescriptions for opioids, being ≥18 years of age, utilizing CSPs for >30 days, utilizing greater than one CSP, having a multiple provider episode, and traveling >25 miles to obtain CSPs were all statistically significant predictors of utilizing concurrent CSPs.
CONCLUSION: The study findings indicate a high prevalence of individuals utilizing concurrent CSPs. This practice is concerning when considering that many overdose deaths result from the concurrent use of CSPs. Prescribers should utilize PDMPs to ensure that aberrant prescription drug behaviors, such as the use of concurrent opioids and benzodiazepines do not readily occur.

Entities:  

Keywords:  Controlled substance prescriptions (CSP); benzodiazepines; muscle relaxants; opioids; prescription drug abuse; prescription drug monitoring programs (PDMP); stimulants

Mesh:

Substances:

Year:  2017        PMID: 28557587     DOI: 10.1080/10826084.2017.1298617

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  5 in total

1.  Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST).

Authors:  Gentry Carter; Ziji Yu; M Aryana Bryan; Jennifer L Brown; T Winhusen; Gerald Cochran
Journal:  Addict Behav       Date:  2021-11-10       Impact factor: 3.913

2.  Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test.

Authors:  Gerald Cochran; Jennifer Brown; Ziji Yu; Stacey Frede; M Aryana Bryan; Andrew Ferguson; Nadia Bayyari; Brooke Taylor; Margie E Snyder; Elizabeth Charron; Omolola A Adeoye-Olatunde; Udi E Ghitza; T Winhusen
Journal:  Drug Alcohol Depend       Date:  2021-09-24       Impact factor: 4.492

3.  Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: a review.

Authors:  Bryn Lindley; Nicholas Cox; Gerald Cochran
Journal:  Integr Pharm Res Pract       Date:  2019-07-19

4.  Concurrent prescriptions for opioids and benzodiazepines and risk of opioid overdose: protocol for a retrospective cohort study using linked administrative data.

Authors:  Erin Y Liu; Robyn Tamblyn; Kristian B Filion; David L Buckeridge
Journal:  BMJ Open       Date:  2021-02-18       Impact factor: 2.692

5.  Provider Characteristics Associated With Outpatient Opioid Prescribing After Surgery.

Authors:  David C Cron; Jay S Lee; James M Dupree; John D Syrjamaki; Hsou Mei Hu; William C Palazzolo; Michael J Englesbe; Chad M Brummett; Jennifer F Waljee
Journal:  Ann Surg       Date:  2020-04       Impact factor: 13.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.